Oct 15, 2026
A landmark study published in The New England Journal of Medicine found that continuous glucose monitoring devices benefit all type 2 diabetes patients, including those not taking insulin, with users achieving lower HbA1c levels and spending approximately 5 more hours per day in target glucose range. The Dexcom CONNECT study marks the first standalone real-time CGM clinical data published in NEJM in nearly two decades.
Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.
A multinational study found that people taking GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound were more than four times as likely to experience nail detachment, along with elevated rates of hair loss and scalp inflammation. Researchers determined that weight loss alone could not fully explain these side effects.
The Advanced Research Projects Agency for Health has awarded more than $100 million to four organizations—MIT, Novelna, NYU, and the University of Washington—to develop biosensor devices for tracking heart disease, inflammation, and perimenopause.
The investigational triple agonist retatrutide demonstrated significant weight loss and improved glycemic control in adults with obesity and type 2 diabetes in the TRIUMPH-2 phase III trial, with some participants losing up to a quarter of their body weight. Results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.
A 12-week study found that creatine supplementation helped middle-aged adults gain muscle and strength even without a structured workout program. When combined with exercise and a calorie-reduced diet, the supplement produced even greater strength gains while helping participants add lean tissue and lose fat.
Analysis of more than 57,000 UK Biobank participants found that greater variation in blood pressure measurements between research visits was associated with increased risk of death, with some blood pressure measures also linked to stroke risk. The findings were presented at the European Association for the Study of Diabetes annual meeting.
A study published in Neurology found that stroke rates among adults ages 20 to 54 nearly doubled over nearly three decades, with blocked blood vessels accounting for much of the increase. Researchers analyzed data from 2,076 first-ever strokes but remain uncertain about the underlying causes of the alarming trend.
A nationwide Danish study found that oral menopausal hormone therapy is associated with elevated risk of venous thromboembolism regardless of dose, while high-dose oral forms also increased stroke and heart attack risk. Transdermal treatments showed no overall increase in thrombotic risk.
Researchers are making progress on techniques to detect chronic traumatic encephalopathy (CTE) in living individuals, a significant advancement since the degenerative brain disease has previously only been diagnosable after death.
Penn State engineers have created temporary smart tattoos capable of monitoring brain waves and detecting heart attacks, while UC San Diego researchers developed a smart ring that tracks four biomarkers in sweat simultaneously, representing advances in real-time health monitoring technology.
Scientists at Kyushu University in Japan have identified a sulfur-based compound called LASSS that protects and enhances a key muscle-repair protein called HGF, potentially offering a way to combat the muscle deterioration that occurs with aging. The compound appears to shield the protein from age-related chemical damage and more than double its strength.
Tech entrepreneur and anti-aging advocate Bryan Johnson announced he has created what he describes as a 'newborn' version of himself using stem cells, with the goal of growing replacement organs after being diagnosed with autoimmune gastritis. The controversial experiment represents his latest effort in his 'Don't Die' longevity campaign.
A new study demonstrates that a blood test measuring p-tau217 levels can identify healthy older adults at high risk of developing Alzheimer's symptoms within five to 10 years, potentially enabling early intervention as prevention trials advance.
Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments in his quest to 'defeat death,' revealed he has been diagnosed with autoimmune gastritis, an incurable condition causing his stomach to 'eat itself.'
Healthcare providers and patients across the United States are reporting intermittent shortages of oral progesterone, a hormone widely used in fertility and menopause treatments. The supply strain reflects growing demand for hormone replacement therapy.
The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.
Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, announced it has raised additional funding at a $1.8 billion valuation, marking significant investor confidence in the anti-aging research space.
New research using brain imaging has revealed three distinct subtypes of ADHD, each associated with different underlying brain systems, co-occurring conditions, and learning challenges. The findings suggest that inattentive and hyperactive-impulsive symptom profiles follow separate neural pathways, potentially enabling more targeted treatment interventions.
A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.
University of Sussex researchers, in collaboration with international scientists, identified a blood test capable of early diagnosis of the most aggressive form of brain cancer, potentially eliminating the need for dangerous surgical biopsies.
A major study presented at ESCMID Global 2026 found that antiretroviral therapy (ART) reduces accelerated biological aging in people with HIV by nearly four years, a finding that could transform understanding of HIV treatment benefits.
Research published in the Canadian Medical Association Journal found that survivors of cancer during their teen and young adult years face twice the risk of developing most types of subsequent cancers compared to the general population.
Five years after initial lupus breakthrough, CAR-T cell therapy continues to demonstrate remissions in autoimmune diseases, generating significant research investment and experimentation beyond its original cancer applications.
A phase 1 clinical trial demonstrated that stem cell transplantation using gene-edited cells rapidly and effectively restored hemoglobin production in five patients with beta-thalassemia, allowing them to discontinue blood transfusions.
Researchers at the Terasaki Institute for Biomedical Innovation developed a smart contact lens that combines real-time intraocular pressure monitoring with responsive drug delivery for glaucoma patients, showing promise in preclinical models.
Cornell researchers have taken a significant step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive, with proof-of-concept results representing progress toward what's considered the 'holy grail' of male contraception.
Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.
Trump administration's 2027 budget proposal calls for cutting $5 billion from the National Institutes of Health and consolidating the number of institutes and centers from 27 to 22, though Congress is unlikely to approve the cuts.
New analysis finds that exposure to chemicals used to make plastic more flexible may have contributed to approximately 1.97 million preterm births in 2018 alone, representing more than 8% of the world's total preterm births that year.